On July 24, 2026, the article titled “REMS Certification and Provider Training Required to Administer Nexplanon” was posted to the Medi-Cal News area on the Medi-Cal Provider website.
Summary:
Effective January 16, 2026, the U.S. Food and Drug Administration (FDA) has approved the Supplemental New Drug Application (sNDA) for Nexplanon® (68 mg etonogestrel implant), extending its approved use from three years to up to five years for pregnancy prevention.
All providers performing Nexplanon® insertions or removals must complete the FDA-required Risk Evaluation and Mitigation Strategy (REMS) certification. Providers should note the following:
- All Nexplanon-trained providers must complete REMS enrollment by August 23, 2026, to continue procuring and inserting Nexplanon®.
- Providers who have not been previously trained by Organon, or those who did not complete the 2018 re-training, can visit the Nexplanon® REMS website to enroll in the REMS program and receive information on the required training.
- All health care providers must receive instruction and training prior to performing insertion and/or removal of Nexplanon®.
To obtain additional information from the manufacturer and enroll in the REMS, visit the Nexplanon REMS website.
The FDA Highlights of Prescribing Information for clinicians and FDA-Approved Patient Labeling documents have been updated.
Additionally, the following provider manual sections have been updated:
- Medi-Cal: Family Planning
- Family Planning, Access, Care and Treatment (Family PACT): Benefits: Family Planning
- Family PACT: Provider Enrollment and Responsibilities